Literature DB >> 25395314

NEOCENT: a randomised feasibility and translational study comparing neoadjuvant endocrine therapy with chemotherapy in ER-rich postmenopausal primary breast cancer.

C Palmieri1, S Cleator, L S Kilburn, S B Kim, S-H Ahn, M Beresford, G Gong, J Mansi, E Mallon, S Reed, K Mousa, L Fallowfield, M Cheang, J Morden, K Page, D S Guttery, B Rghebi, L Primrose, J A Shaw, A M Thompson, J M Bliss, R C Coombes.   

Abstract

Neoadjuvant endocrine therapy is an alternative to chemotherapy for women with oestrogen receptor (ER)-positive early breast cancer (BC). We aimed to assess feasibility of recruiting patients to a study comparing chemotherapy versus endocrine therapy in postmenopausal women with ER-rich primary BC, and response as well as translational endpoints were assessed. Patients requiring neoadjuvant therapy were randomised to chemotherapy: 6 × 3-weekly cycles FE₁₀₀C or endocrine therapy: letrozole 2.5 mg, daily for 18-23 weeks. Primary endpoints were recruitment feasibility and tissue collection. Secondary endpoints included clinical, radiological and pathological response rates, quality of life and translational endpoints. 63/80 patients approached were eligible, of those 44 (70, 95% CI 57-81) were randomised. 12 (54.5, 95% CI 32.2-75.6) chemotherapy patients showed radiological objective response compared with 13 (59.1, 95% CI 36.4-79.3) letrozole patients. Compared with baseline, mean Ki-67 levels fell in both groups at days 2-4 and at surgery [fold change: 0.24 (95% CI 0.12-0.51) and 0.24; (95% CI 0.15-0.37), respectively]. Plasma total cfDNA levels rose from baseline to week 8 [fold change: chemotherapy 2.10 (95% CI 1.47-3.00), letrozole 1.47(95% CI 0.98-2.20)], and were maintained at surgery in the chemotherapy group [chemotherapy 2.63; 95% CI 1.56-4.41), letrozole 0.95 (95% CI 0.71-1.26)]. An increase in plasma let-7a miRNA was seen at surgery for patients with objective radiological response to chemotherapy. Recruitment and tissue collection endpoints were met; however, a larger trial was deemed unfeasible due to slow accrual. Both regimens were equally efficacious. Dynamic changes were seen in Ki-67 and circulating biomarkers in both groups with increases in cfDNA and let-7a miRNA persisting until surgery for chemotherapy patients.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25395314     DOI: 10.1007/s10549-014-3183-4

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  28 in total

Review 1.  Neoadjuvant endocrine therapy: A potential strategy for ER-positive breast cancer.

Authors:  Li-Tong Yao; Mo-Zhi Wang; Meng-Shen Wang; Xue-Ting Yu; Jing-Yi Guo; Tie Sun; Xin-Yan Li; Ying-Ying Xu
Journal:  World J Clin Cases       Date:  2019-08-06       Impact factor: 1.337

Review 2.  Current Status of Neoadjuvant Endocrine Therapy in Early Stage Breast Cancer.

Authors:  Tomás Reinert; Rodrigo Gonçalves; Matthew J Ellis
Journal:  Curr Treat Options Oncol       Date:  2018-04-16

Review 3.  miRNAs as therapeutic predictors and prognostic biomarkers of neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis.

Authors:  Zhuo Zhang; Hanxu Zhang; Jiao Yu; Ling Xu; Xiaocong Pang; Qian Xiang; Qianxin Liu; Yimin Cui
Journal:  Breast Cancer Res Treat       Date:  2022-06-21       Impact factor: 4.624

4.  Synchronous Operable Pancreatic and Breast Cancer Without Genetic Mutation: A Literature Review and Discussion.

Authors:  Adam Ofri; Danika Zuidersma; Connie I Diakos; Amanda Stevanovic; Matthew Wong; Samriti Sood; Jaswinder S Samra; Anthony J Gill; Anubhav Mittal
Journal:  Front Surg       Date:  2022-06-24

5.  Study protocol: Randomized, open-label, non-inferiority clinical trial for evaluating the clinical and pathological response rates to neoadjuvant hormone therapy and chemotherapy in patients with luminal-subtype breast tumors.

Authors:  Maria Carolina Gouveia; Candice Amorim de Araújo Lima Santos; Ariani Impieri Souza
Journal:  Contemp Clin Trials Commun       Date:  2022-10-08

6.  Benefit of the addition of hormone therapy to neoadjuvant anthracycline-based chemotherapy for breast cancer: comparison of predicted and observed pCR.

Authors:  Daniele Generali; Silvia Paola Corona; Lajos Pusztai; Roman Rouzier; Giovanni Allevi; Sergio Aguggini; Manuela Milani; Carla Strina; Albane Frati
Journal:  J Cancer Res Clin Oncol       Date:  2018-01-17       Impact factor: 4.553

7.  Neoadjuvant endocrine therapy in breast cancer patients.

Authors:  Raquel Lobo-Cardoso; André Torres Magalhães; José Luís Fougo
Journal:  Porto Biomed J       Date:  2017-05-02

8.  Network Meta-Analysis of the Effectiveness of Neoadjuvant Endocrine Therapy for Postmenopausal, HR-Positive Breast Cancer.

Authors:  Wei Wang; Chenghao Liu; Wenbin Zhou; Tiansong Xia; Hui Xie; Shui Wang
Journal:  Sci Rep       Date:  2016-05-13       Impact factor: 4.379

Review 9.  Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer: A Systematic Review and Meta-analysis.

Authors:  Laura M Spring; Arjun Gupta; Kerry L Reynolds; Michele A Gadd; Leif W Ellisen; Steven J Isakoff; Beverly Moy; Aditya Bardia
Journal:  JAMA Oncol       Date:  2016-11-01       Impact factor: 31.777

10.  Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: a randomized pilot trial.

Authors:  Wei Wu; Jiewen Chen; Heran Deng; Liang Jin; Zhanghai He; Nanyan Rao; Yan Nie; Yandan Yao; Yaping Yang; Fengxi Su; Jieqiong Liu
Journal:  BMC Cancer       Date:  2021-07-27       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.